Advanced search
Publication Cover
Future Neurology Volume 7, 2012 - Issue 6
Submit an article Journal homepage
142
Views
0
CrossRef citations to date
0
Altmetric
Perspective

The Neuro-Ophthalmology of Multiple Sclerosis

Ryan D Walsh1 Departments of Neurology & Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, 3 W Gates Building, Philadelphia, PA19104, USACorrespondence[email protected]
View further author information
,
Collin M McClelland1 Departments of Neurology & Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, 3 W Gates Building, Philadelphia, PA19104, USAView further author information
&
Steven L Galetta1 Departments of Neurology & Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, 3 W Gates Building, Philadelphia, PA19104, USAView further author information
Pages 679-700 | Published online: 07 Nov 2012

References

  • Dutta R , TrappBD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology68(22 Suppl. 3), S22–31; discussion S43–54 (2007).
  • Vogt J , PaulF, AktasOet al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol.66(3), 310–322 (2009).
  • Gray E , RiceC, NightingaleHet al. Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Mult. Scler. doi:10.1177/1352458512451661 (2012) (Epub ahead of print).
  • Noonan CW , WilliamsonDM, HenryJPet al. The prevalence of multiple sclerosis in 3 US communities. Prev. Chronic Dis.7(1), A12 (2010).
  • Percy AK , NobregaFT, KurlandLT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch. Ophthalmol.87(2), 135–139 (1972).
  • Muri RM , MeienbergO. The clinical spectrum of internuclear ophthalmoplegia in multiple sclerosis. Arch. Neurol.42(9), 851–855 (1985).
  • Downey DL , StahlJS, BhidayasiriRet al. Saccadic and vestibular abnormalities in multiple sclerosis: sensitive clinical signs of brainstem and cerebellar involvement. Ann. NY Acad. Sci.956, 438–440 (2002).
  • Serra A , DerwenskusJ, DowneyDL, LeighRJ. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J. Neurol.250(5), 569–575 (2003).
  • The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch. Ophthalmol.109(12), 1673–1678 (1991).
  • The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology49(5), 1404–1413 (1997).
  • Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol.65(6), 727–732 (2008).
  • Beck RW , TrobeJD, MokePSet al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch. Ophthalmol.121(7), 944–949 (2003).
  • Dunker S , WiegandW. Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis. Ophthalmology103(11), 1768–1773 (1996).
  • Rizzo JF , 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology109(9), 1679–1684 (2002).
  • Lepore FE . The origin of pain in optic neuritis. Determinants of pain in 101 eyes with optic neuritis. Arch. Neurol.48(7), 748–749 (1991).
  • Neuro-Ophthalmology: Diagnosis and Management (2nd Edition). LiuGT, VolpeNJ, GalettaS(Eds) . Elsevier, Philadelphia, PA, USA (2010).
  • Katz B . The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans. Am. Ophthalmol. Soc.93, 685–708 (1995).
  • Pau D , Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic neuritis. Eye (Lond.)25(7), 833–842 (2011).
  • Jackson A , SheppardS, JohnsonAC, AnnesleyD, LaittRD, KassnerA. Combined fat- and water-suppressed MR imaging of orbital tumors. AJNR Am. J. Neuroradiol.20(10), 1963–1969 (1999).
  • Khanna S , SharmaA, HueckerJ, GordonM, NaismithRT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J. Neuroophthalmol.32(3), 216–220 (2012).
  • Guy J , MaoJ, BidgoodWD Jr, Mancuso A, Quisling RG. Enhancement and demyelination of the intraorbital optic nerve. Fat suppression magnetic resonance imaging. Ophthalmology99(5), 713–719 (1992).
  • Hendrix LE , KneelandJB, HaughtonVMet al. MR imaging of optic nerve lesions: value of gadopentetate dimeglumine and fat-suppression technique. AJNR Am. J. Neuroradiol.11(4), 749–754 (1990).
  • Aiken AH , MukherjeeP, GreenAJ, GlastonburyCM. MR imaging of optic neuropathy with extended echo-train acquisition fluid-attenuated inversion recovery. AJNR Am. J. Neuroradiol.32(2), 301–305 (2011).
  • Jackson A , SheppardS, LaittRD, KassnerA, MoriartyD. Optic neuritis: MR imaging with combined fat- and water-suppression techniques. Radiology206(1), 57–63 (1998).
  • Balcer LJ , BaierML, CohenJAet al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology61(10), 1367–1373 (2003).
  • Balcer LJ , BaierML, PelakVSet al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult. Scler.6(3), 163–171 (2000).
  • Halliday AM , McDonaldWI, MushinJ. Delayed visual evoked response in optic neuritis. Lancet1(7758), 982–985 (1972).
  • Halliday AM , McDonaldWI, MushinJ. Visual evoked response in diagnosis of multiple sclerosis. Br. Med. J.4(5893), 661–664 (1973).
  • Sisto D , TrojanoM, VetrugnoM, TrabuccoT, IlicetoG, SborgiaC. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol. Vis. Sci.46(4), 1264–1268 (2005).
  • Fraser CL , KlistornerA, GrahamSL, GarrickR, BillsonFA, GriggJR. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology113(2), 323.e1–323.e2 (2006).
  • Thurtell MJ , BalaE, YaniglosSS, RuckerJC, PeacheyNS, LeighRJ. Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials. Neurology73(22), 1849–1857 (2009).
  • Horwitz H , DegnM, ModvigS, LarssonHB, WanscherB, FrederiksenJL. CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis. J. Neurol. doi:10.1007/s00415-012-6551-1 (2012) (Epub ahead of print).
  • Fraser C , KlistornerA, GrahamS, GarrickR, BillsonF, GriggJ. Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch. Neurol.63(6), 847–850 (2006).
  • Sakai RE , FellerDJ, GalettaKM, GalettaSL, BalcerLJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J. Neuroophthalmol.31(4), 362–373 (2011).
  • Bock M , BrandtAU, KuchenbeckerJet al. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br. J. Ophthalmol.96(1), 62–67 (2012).
  • Fisher JB , JacobsDA, MarkowitzCEet al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology113(2), 324–332 (2006).
  • Trip SA , SchlottmannPG, JonesSJet al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann. Neurol.58(3), 383–391 (2005).
  • Talman LS , BiskerER, SackelDJet al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann. Neurol.67(6), 749–760 (2010).
  • Costello F , HodgeW, PanYI, EggenbergerE, FreedmanMS. Using retinal architecture to help characterize multiple sclerosis patients. Can. J. Ophthalmol.45(5), 520–526 (2010).
  • Beck RW , ClearyPA. Optic neuritis treatment trial. One-year follow-up results. Arch. Ophthalmol.111(6), 773–775 (1993).
  • Ruprecht K , KlinkerE, DintelmannT, RieckmannP, GoldR. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology63(6), 1081–1083 (2004).
  • Koziolek MJ , TampeD, BahrMet al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J. Neuroinflammation9(1), 80 (2012).
  • Kupersmith MJ , GalRL, BeckRW, XingD, MillerN. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology69(6), 508–514 (2007).
  • Scholl GB , SongHS, WraySH. Uhthoff‘s symptom in optic neuritis: relationship to magnetic resonance imaging and development of multiple sclerosis. Ann. Neurol.30(2), 180–184 (1991).
  • Beck RW , ClearyPA, TrobeJDet al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N. Engl. J. Med.329(24), 1764–1769 (1993).
  • Chrousos GA , KattahJC, BeckRW, ClearyPA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA269(16), 2110–2112 (1993).
  • Beck RW , GalRL, BhattiMTet al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am. J. Ophthalmol.137(1), 77–83 (2004).
  • Sellebjerg F , NielsenHS, FrederiksenJL, OlesenJ. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology52(7), 1479–1484 (1999).
  • Cole SR , BeckRW, MokePS, KaufmanDI, TourtellotteWW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology51(3), 885–887 (1998).
  • Soderstrom M , Ya-PingJ, HillertJ, LinkH. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology50(3), 708–714 (1998).
  • Jacobs LD , KabaSE, MillerCM, PrioreRL, BrownscheidleCM. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann. Neurol.41(3), 392–398 (1997).
  • Simo M , BarsiP, AranyiZ. Predictive role of evoked potential examinations in patients with clinically isolated optic neuritis in light of the revised McDonald criteria. Mult. Scler.14(4), 472–478 (2008).
  • Costello F , HodgeW, PanYI, MetzL, KardonRH. Retinal nerve fiber layer and future risk of multiple sclerosis. Can. J. Neurol. Sci.35(4), 482–487 (2008).
  • Comi G , FilippiM, BarkhofFet al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357(9268), 1576–1582 (2001).
  • Jacobs LD , BeckRW, SimonJHet al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N. Engl. J. Med.343(13), 898–904 (2000).
  • Comi G , De StefanoN, FreedmanMSet al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a Phase 3 randomised controlled trial. Lancet Neurol.11(1), 33–41 (2012).
  • Kappos L , PolmanCH, FreedmanMSet al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67(7), 1242–1249 (2006).
  • Comi G , MartinelliV, RodegherMet al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet374(9700), 1503–1511 (2009).
  • Kappos L , FreedmanMS, PolmanCHet al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the Phase 3 BENEFIT trial. Lancet Neurol.8(11), 987–997 (2009).
  • Kerr NM , ChewSS, Danesh-MeyerHV. Non-arteritic anterior ischaemic optic neuropathy: a review and update. J. Clin. Neurosci.16(8), 994–1000 (2009).
  • Mowry EM , BalcerLJ, GalettaSL. Multiple sclerosis and the ophthalmologist. Compr. Ophthalmol. Update8(1), 39–49 (2007).
  • Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA273(8), 625–632 (1995).
  • Swartz NG , BeckRW, SavinoPJet al. Pain in anterior ischemic optic neuropathy. J. Neuroophthalmol.15(1), 9–10 (1995).
  • Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch. Ophthalmol.114(11), 1366–1374 (1996).
  • Wingerchuk DM . Diagnosis and treatment of neuromyelitis optica. Neurologist13(1), 2–11 (2007).
  • Merle H , OlindoS, BonnanMet al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology114(4), 810–815 (2007).
  • Collongues N , MarignierR, ZephirHet al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology74(9), 736–742 (2010).
  • Wingerchuk DM , HogancampWF, O‘BrienPC, WeinshenkerBG. The clinical course of neuromyelitis optica (Devic‘s syndrome). Neurology53(5), 1107–1114 (1999).
  • Lai C , TianG, TakahashiT, LiuW, YangL, ZhangX. Neuromyelitis optica antibodies in patients with severe optic neuritis in China. J. Neuroophthalmol.31(1), 16–19 (2011).
  • Jarius S , FrederiksonJ, WatersPet al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J. Neurol. Sci.298(1–2), 158–162 (2010).
  • Costa C , ArrambideG, TintoreMet al. Value of NMO-IgG determination at the time of presentation as CIS. Neurology78(20), 1608–1611 (2012).
  • Matiello M , LennonVA, JacobAet al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology70(23), 2197–2200 (2008).
  • Shimizu J , HatanakaY, HasegawaMet al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology75(16), 1423–1427 (2010).
  • Papeix C , VidalJS, de SezeJet al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult. Scler.13(2), 256–259 (2007).
  • Kleiter I , HellwigK, BertheleAet al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch. Neurol.69(2), 239–245 (2012).
  • Min JH , KimBJ, LeeKH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult. Scler.18(1), 113–115 (2012).
  • Chacko JG , LamBL, AdusumilliJ, DubovySR. Multicentric malignant glioma of adulthood masquerading as optic neuritis. Br. J. Ophthalmol.94(6), 782–783, 812 (2010).
  • Maitland CG , MillerNR. Neuroretinitis. Arch. Ophthalmol.102(8), 1146–1150 (1984).
  • Chi SL , StinnettS, EggenbergerEet al. Clinical characteristics in 53 patients with cat scratch optic neuropathy. Ophthalmology119(1), 183–187 (2012).
  • Parmley VC , SchiffmanJS, MaitlandCG, MillerNR, DreyerRF, HoytWF. Does neuroretinitis rule out multiple sclerosis? Arch. Neurol.44(10), 1045–1048 (1987).
  • Cohen JA , BarkhofF, ComiGet al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
  • Kappos L , AntelJ, ComiGet al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355(11), 1124–1140 (2006).
  • Kappos L , RadueEW, O‘ConnorPet al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
  • Jain N , BhattiMT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology78(9), 672–680 (2012).
  • Ross A , RossAH, MohamedQ. Review and update of central serous chorioretinopathy. Curr. Opin. Ophthalmol.22(3), 166–173 (2011).
  • Bouzas EA , KaradimasP, PournarasCJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol.47(5), 431–448 (2002).
  • Hornabrook RS , MillerDH, NewtonMRet al. Frequent involvement of the optic radiation in patients with acute isolated optic neuritis. Neurology42(1), 77–79 (1992).
  • Plant GT , KermodeAG, TuranoGet al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology42(1), 68–76 (1992).
  • Brooks BR , WalkerDL. Progressive multifocal leukoencephalopathy. Neurol. Clin.2(2), 299–313 (1984).
  • Berger JR , PallL, LanskaD, WhitemanM. Progressive multifocal leukoencephalopathy in patients with HIV infection. J. Neurovirol.4(1), 59–68 (1998).
  • Clifford DB , De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol.9(4), 438–446 (2010).
  • Jacobs DA , GalettaSL. Multiple sclerosis and the visual system. Ophthalmol. Clin. North Am.17(3), 265–273 (2004).
  • Chen L , GordonLK. Ocular manifestations of multiple sclerosis. Curr. Opin. Ophthalmol.16(5), 315–320 (2005).
  • Edwards LJ , ConstantinescuCS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult. Scler.10(5), 575–581 (2004).
  • Langer-Gould A , AlbersKB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult. Scler.16(7), 855–861 (2010).
  • Maca SM , ScharitzerM, Barisani-AsenbauerT. Uveitis and neurologic diseases: an often overlooked relationship. Wien Klin. Wochenschr.118(9–10), 273–279 (2006).
  • Donaldson MJ , PulidoJS, HermanDC, DiehlN, HodgeD. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am. J. Ophthalmol.144(6), 812–817 (2007).
  • Tilikete C , JasseL, VukusicSet al. Persistent ocular motor manifestations and related visual consequences in multiple sclerosis. Ann. NY Acad. Sci.1233, 327–334 (2011).
  • Derwenskus J , RuckerJC, SerraAet al. Abnormal eye movements predict disability in MS: two-year follow-up. Ann. NY Acad. Sci.1039, 521–523 (2005).
  • Tintore M , RoviraA, ArrambideGet al. Brainstem lesions in clinically isolated syndromes. Neurology75(21), 1933–1938 (2010).
  • Zee DS . Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin. Neurol.1(2), 455–470 (1992).
  • Cogan DG . Internuclear ophthalmoplegia, typical and atypical. Arch. Ophthalmol.84(5), 583–589 (1970).
  • Neuroanatomy Through Clinical Cases. BlumenfeldH (Ed.). Sinauer, Sunderland, MA, USA (2002).
  • Frohman EM , FrohmanTC, ZeeDS, McCollR, GalettaS. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol.4(2), 111–121 (2005).
  • Zee DS , HainTC, CarlJR. Abduction nystagmus in internuclear ophthalmoplegia. Ann. Neurol.21(4), 383–388 (1987).
  • Meienberg O , MuriR, RabineauPA. Clinical and oculographic examinations of saccadic eye movements in the diagnosis of multiple sclerosis. Arch. Neurol.43(5), 438–443 (1986).
  • Jozefowicz-Korczynska M , LukomskiM, PajorA. Identification of internuclear ophthalmoplegia signs in multiple sclerosis patients. Saccade test analysis. J. Neurol.255(7), 1006–1011 (2008).
  • Keane JR . Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. Arch. Neurol.62(5), 714–717 (2005).
  • Bolanos I , LozanoD, CantuC. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol. Scand.110(3), 161–165 (2004).
  • Sierra-Hidalgo F , Moreno-RamosT, VillarejoAet al. A variant of WEBINO syndrome after top of the basilar artery stroke. Clin. Neurol. Neurosurg.112(9), 801–804 (2010).
  • Shinoda K , MatsushitaT, FurutaKet al. Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody. Mult. Scler.17(7), 885–887 (2011).
  • Frohman TC , GravesJ, BalcerLJ, GalettaSL, FrohmanEM. The neuro-ophthalmology of multiple sclerosis. Continuum Lifelong Learning Neurol.16(5), 122–146 (2010).
  • Mills DA , FrohmanTC, DavisSLet al. Break in binocular fusion during head turning in MS patients with INO. Neurology71(6), 458–460 (2008).
  • Flipse JP , StraathofCS, Van der SteenJet al. Binocular saccadic eye movements in multiple sclerosis. J. Neurol. Sci.148(1), 53–65 (1997).
  • Frohman TC , FrohmanEM, O‘SuilleabhainPet al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology61(6), 848–850 (2003).
  • Frohman EM , O‘SuilleabhainP, DeweyRBJr., FrohmanTC, KramerPD, A new measure of dysconjugacy in INO: the first-pass amplitude. J. Neurol. Sci.210(1–2), 65–71 (2003).
  • Frohman EM , FrohmanTC, O‘SuilleabhainPet al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J. Neurol. Neurosurg. Psychiatry73(1), 51–55 (2002).
  • Frohman EM , ZhangH, KramerPDet al. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology57(5), 762–768 (2001).
  • Wall M , WraySH. The one-and-a-half syndrome – a unilateral disorder of the pontine tegmentum: a study of 20 cases and review of the literature. Neurology33(8), 971–980 (1983).
  • Espinosa PS . Teaching NeuroImage: one-and-a-half syndrome. Neurology70(5), e20 (2008).
  • de Seze J , VukusicS, Viallet-MarcelMet al. Unusual ocular motor findings in multiple sclerosis. J. Neurol. Sci.243(1–2), 91–95 (2006).
  • Frohman EM , FrohmanTC. Horizontal monocular saccadic failure: an unusual clinically isolated syndrome progressing to multiple sclerosis. Mult. Scler.9(1), 55–58 (2003).
  • Brigell MG , GoodwinJA, LoranceR. Saccadic latency as a measure of afferent visual conduction. Invest. Ophthalmol. Vis. Sci.29(8), 1331–1338 (1988).
  • Reulen JP , SandersEA, HogenhuisLA. Eye movement disorders in multiple sclerosis and optic neuritis. Brain106(Pt 1), 121–140 (1983).
  • Karatas M . Internuclear and supranuclear disorders of eye movements: clinical features and causes. Eur. J. Neurol.16(12), 1265–1277 (2009).
  • Schon F , HodgsonTL, MortD, KennardC. Ocular flutter associated with a localized lesion in the paramedian pontine reticular formation. Ann. Neurol.50(3), 413–416 (2001).
  • King SA , SchneiderRM, SerraA, LeighRJ. Critical role of cerebellar fastigial nucleus in programming sequences of saccades. Ann. NY Acad. Sci.1233, 155–161 (2011).
  • Frohman EM , FrohmanTC, FleckensteinJ, RackeMK, HawkerK, KramerPD. Ocular contrapulsion in multiple sclerosis: clinical features and pathophysiological mechanisms. J. Neurol. Neurosurg. Psychiatry70(5), 688–692 (2001).
  • Thurtell MJ , LeighRJ. Therapy for nystagmus. J. Neuroophthalmol.30(4), 361–371 (2010).
  • Averbuch-Heller L , ZivotofskyAZ, DasVE, DiScennaAO, LeighRJ. Investigations of the pathogenesis of acquired pendular nystagmus. Brain118(Pt 2), 369–378 (1995).
  • Das VE , OrugantiP, KramerPD, LeighRJ. Experimental tests of a neural-network model for ocular oscillations caused by disease of central myelin. Exp. Brain Res.133(2), 189–197 (2000).
  • Lopez LI , BronsteinAM, GrestyMA, Du Boulay EP, Rudge P. Clinical and MRI correlates in 27 patients with acquired pendular nystagmus. Brain119(Pt 2), 465–472 (1996).
  • Barton JJ , CoxTA. Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy. J. Neurol. Neurosurg. Psychiatry56(3), 262–267 (1993).
  • Starck M , AlbrechtH, PollmannW, DieterichM, StraubeA. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J. Neurol.257(3), 322–327 (2010).
  • Thurtell MJ , JoshiAC, LeoneACet al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann. Neurol.67(5), 676–680 (2010).
  • Villoslada P , ArrondoG, SepulcreJ, AlegreM, ArtiedaJ. Memantine induces reversible neurologic impairment in patients with MS. Neurology72(19), 1630–1633 (2009).
  • Sandramouli S , BenamerHT, MantleM, ChavanR. See-saw nystagmus as the presenting sign in multiple sclerosis. J. Neuroophthalmol.25(1), 56–57 (2005).
  • Minagar A , SheremataWA, TusaRJ. Perverted head-shaking nystagmus: a possible mechanism. Neurology57(5), 887–889 (2001).
  • Matsumoto S , OhyagiY, InoueIet al. Periodic alternating nystagmus in a patient with MS. Neurology56(2), 276–277 (2001).
  • Barton JJ , CoxTA, DigreKB. Acquired convergence-evoked pendular nystagmus in multiple sclerosis. J. Neuroophthalmol.19(1), 34–38 (1999).
  • Jasse L , VighettoA, VukusicS, PelissonD, TiliketeC. Unusual monocular pendular nystagmus in multiple sclerosis. J. Neuroophthalmol.31(1), 38–41 (2011).
  • Ohkoshi N , KomatsuY, MizusawaH, KanazawaI. Primary position upbeat nystagmus increased on downward gaze: clinicopathologic study of a patient with multiple sclerosis. Neurology50(2), 551–553 (1998).
  • Thomke F , LenschE, RingelK, HopfHC. Isolated cranial nerve palsies in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry63(5), 682–685 (1997).
  • Keane JR . Third nerve palsy: analysis of 1400 personally-examined inpatients. Can. J. Neurol. Sci.37(5), 662–670 (2010).
  • Rucker CW . Paralysis of the third, fourth and sixth cranial nerves. Am. J. Ophthalmol.46(6), 787–794 (1958).
  • Rucker CW . The causes of paralysis of the third, fourth and sixth cranial nerves. Am. J. Ophthalmol.61(5 Pt 2), 1293–1298 (1966).
  • Rush JA , YoungeBR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch. Ophthalmol.99(1), 76–79 (1981).
  • Richards BW , JonesFR Jr, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am. J. Ophthalmol.113(5), 489–496 (1992).
  • Berlit P . Isolated and combined pareses of cranial nerves III, IV and VI. A retrospective study of 412 patients. J. Neurol. Sci.103(1), 10–15 (1991).
  • Zadro I , BarunB, HabekM, BrinarVV. Isolated cranial nerve palsies in multiple sclerosis. Clin. Neurol. Neurosurg.110(9), 886–888 (2008).
  • Newman NJ , LessellS. Isolated pupil-sparing third-nerve palsy as the presenting sign of multiple sclerosis. Arch. Neurol.47(7), 817–818 (1990).
  • Beleza P , MachadoA, Soares-FernandesJet al. Isolated oculomotor nerve paresis as the presenting sign of multiple sclerosis. Arq. Neuropsiquiatr.66(2A), 254–255 (2008).
  • Lee AG , TangRA, WongGG, SchiffmanJS, SinghS. Isolated inferior rectus muscle palsy resulting from a nuclear third nerve lesion as the initial manifestation of multiple sclerosis. J. Neuroophthalmol.20(4), 246–247 (2000).
  • Bentley PI , KimberT, SchapiraAH. Painful third nerve palsy in MS. Neurology58(10), 1532 (2002).
  • Gnanaraj L , RaoVJ. Partial unilateral third nerve palsy and bilateral internuclear ophthalmoplegia: an unusual presentation of multiple sclerosis. Eye (Lond.)14(Pt 4), 673–675 (2000).
  • Keane JR . Fourth nerve palsy: historical review and study of 215 inpatients. Neurology43(12), 2439–2443 (1993).
  • Jacobson DM , MosterML, EggenbergerER, GalettaSL, LiuGT. Isolated trochlear nerve palsy in patients with multiple sclerosis. Neurology53(4), 877–879 (1999).
  • Patel SV , MutyalaS, LeskeDA, HodgeDO, HolmesJM. Incidence, associations, and evaluation of sixth nerve palsy using a population-based method. Ophthalmology111(2), 369–375 (2004).
  • Moster ML , SavinoPJ, SergottRC, BosleyTM, SchatzNJ. Isolated sixth-nerve palsies in younger adults. Arch. Ophthalmol.102(9), 1328–1330 (1984).
  • Peters GB 3rd, Bakri SJ, Krohel GB. Cause and prognosis of nontraumatic sixth nerve palsies in young adults. Ophthalmology109(10), 1925–1928 (2002).
  • Barr D , KupersmithMJ, TurbinR, BoseS, RothR. Isolated sixth nerve palsy: an uncommon presenting sign of multiple sclerosis. J. Neurol.247(9), 701–704 (2000).
  • Rose JW , DigreKB, LynchSG, HarnsbergerRH. Acute VIth cranial nerve dysfunction in multiple sclerosis. Evaluation by magnetic resonance imaging. J. Clin. Neuroophthalmol.12(1), 17–20 (1992).
  • Bartosik-Psujek H , PsujekM, StelmasiakZ. Rare first symptoms of multiple sclerosis. Ann. Univ. Mariae Curie Sklodowska Med.59(1), 242–244 (2004).
  • Robertson DM , HinesJD, RuckerCW. Acquired sixth-nerve paresis in children. Arch. Ophthalmol.83(5), 574–579 (1970).
  • Kodsi SR , YoungeBR. Acquired oculomotor, trochlear, and abducent cranial nerve palsies in pediatric patients. Am. J. Ophthalmol.114(5), 568–574 (1992).
  • Afifi AK , BellWE, MenezesAH. Etiology of lateral rectus palsy in infancy and childhood. J Child Neurol.7(3), 295–299 (1992).
  • Lee MS , GalettaSL, VolpeNJ, LiuGT. Sixth nerve palsies in children. Pediatr Neurol.20(1), 49–52 (1999).
  • Merino P , Gomez de Liano P, Villalobo JM, Franco G, Gomez de Liano R. Etiology and treatment of pediatric sixth nerve palsy. J. AAPOS.14(6), 502–505 (2010).
  • Jozefowicz-Korczynska M , PajorAM. Evaluation of the smooth pursuit tests in multiple sclerosis patients. J. Neurol.258(10), 1795–1800 (2011).
  • Frohman TC , GalettaS, FoxRet al. Pearls & Oy-sters: the medial longitudinal fasciculus in ocular motor physiology. Neurology70(17), e57–e67 (2008).
  • Brodsky MC , DonahueSP, VaphiadesM, BrandtT. Skew deviation revisited. Surv. Ophthalmol.51(2), 105–128 (2006).
  • Halmagyi GM , CurthoysIS. A clinical sign of canal paresis. Arch. Neurol.45(7), 737–739 (1988).
  • Proudlock FA , GottlobI, ConstantinescuCS. Oscillopsia without nystagmus caused by head titubation in a patient with multiple sclerosis. J. Neuroophthalmol.22(2), 88–91 (2002).
  • Shaikh AG , ReichS, ZeeDS. Pseudonystagmus – clinical features and quantitative characteristics. Nat. Rev. Neurol.6(9), 519–523 (2010).
  • Frohman EM , DeweyRB, FrohmanTC. An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. Mult. Scler.10(3), 322–325 (2004).
  • Lee WB , BergerJR, O‘HalloranHS. Parinaud syndrome heralding MS. Neurology60(2), 322 (2003).
  • Slyman JF , KlineLB. Dorsal midbrain syndrome in multiple sclerosis. Neurology31(2), 196–198 (1981).
  • Agarwal PK , LimLT, ParkS, Spiteri-CornishK, CoxA. Alternating Horner‘s syndrome in multiple sclerosis. Semin. Ophthalmol.27(1–2), 40–41 (2012).
  • Fox EJ , RhoadesRW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr. Opin. Neurol.25(Suppl.), S11–S19 (2012).
  • Kappos L , GoldR, MillerDHet al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet372(9648), 1463–1472 (2008).
  • Schimrigk S , BruneN, HellwigKet al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol.13(6), 604–610 (2006).
  • Perumal J , KhanO. Emerging disease-modifying therapies in multiple sclerosis. Curr. Treat. Options Neurol.14, 256–263 (2012).
  • O‘Connor PW , LiD, FreedmanMSet al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66(6), 894–900 (2006).
  • O‘Connor P , WolinskyJS, ConfavreuxCet al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med.365(14), 1293–1303 (2011).
  • Ji B , LiM, WuWTet al. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol. Cell. Neurosci.33(3), 311–320 (2006).
  • Mi S , HuB, HahmKet al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med.13(10), 1228–1233 (2007).
  • Matta M , LeighRJ, PugliattiM, AielloI, SerraA. Using fast eye movements to study fatigue in multiple sclerosis. Neurology73(10), 798–804 (2009).
  • Finke C , PechLM, SommerCet al. Dynamics of saccade parameters in multiple sclerosis patients with fatigue. J. Neurol. doi:10.1007/s00415-012-6565-8 (2012) (Epub ahead of print).
  • van der Kolk AG , HendrikseJ, ZwanenburgJJ, VisserF, LuijtenPR. Clinical applications of 7T MRI in the brain. Eur. J. Radiol. doi:10.1016/j.ejrad.07.007 (2011).
  • Sinnecker T , MittelstaedtP, DorrJet al. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. Arch. Neurol.69(6), 739–745, (2012).
  • Tallantyre EC , DixonJE, DonaldsonIet al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology76(6), 534–539 (2011).
  • Sinnecker T , DorrJ, PfuellerCFet al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology79(7), 708–714 (2012).
  • Wuerfel J , SinneckerT, RingelsteinEBet al. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult. Scler. doi:10.1177/1352458512441270 (2012) (Epub ahead of print).
  • Fox RJ , BeallE, BhattacharyyaP, ChenJT, SakaieK. Advanced MRI in multiple sclerosis: current status and future challenges. Neurol. Clin.29(2), 357–380 (2011).
  • Naismith RT , XuJ, TutlamNTet al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch. Neurol.69(1), 65–71 (2012).
  • Ratchford JN , QuiggME, CongerAet al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology73(4), 302–308 (2009).
  • Naismith RT , TutlamNT, XuJet al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology72(12), 1077–1082 (2009).
  • Brandt AU , ZimmermannH, KaufholdFet al. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS. PLoS ONE7(6), e38741 (2012).
  • Frohman EM , FujimotoJG, FrohmanTC, CalabresiPA, CutterG, BalcerLJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat. Clin. Pract. Neurol.4(12), 664–675 (2008).
  • Petzold A , de BoerJF, SchipplingSet al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol.9(9), 921–932 (2010).
  • Gordon-Lipkin E , ChodkowskiB, ReichDSet al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology69(16), 1603–1609 (2007).
  • Siger M , DziegielewskiK, JasekLet al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J. Neurol.255(10), 1555–1560 (2008).
  • Dorr J , WerneckeKD, BockMet al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS ONE6(4), e18132 (2011).
  • Costello F . Evaluating the use of optical coherence tomography in optic neuritis. Mult. Scler. Int.2011, 148394 (2011).
  • Seigo MA , SotirchosES, NewsomeSet al. In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. J. Neurol.259(10), 2119–2130 (2012).
  • Saidha S , SycSB, DurbinMKet al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult. Scler.17(12), 1449–1463 (2011).
  • Walter SD , IshikawaH, GalettaKMet al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology119(6), 1250–1257 (2012).
  • Smith RM , OommenBS, StahlJS. Image-shifting optics for a nystagmus treatment device. J. Rehabil. Res. Dev.41(3A), 325–336 (2004).
  • Smith RM , OommenBS, StahlJS. Application of adaptive filters to visual testing and treatment in acquired pendular nystagmus. J. Rehabil. Res. Dev.41(3A), 313–324 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.